Results 231 to 240 of about 227,662 (304)

Impact of Age on Lipid-Lowering Therapy Prescriptions and LDL-Cholesterol Control: Insights from the PORTRAIT-DYS Study. [PDF]

Glob Heart
Gavina C, Seabra D, Oliveira S, Teixeira C, Ruivo JA, Lourenço-Silva N, Luz AR, Jácome C, Araújo F.   +8 more
europepmc   +1 more source

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The American Diabetes Association recommends achieving treatment goals (glycated haemoglobin ≤ 53 mmol/mol [7.0%], blood pressure < 130/80 mmHg, low‐density lipoprotein cholesterol < 1.81 mmol/L and use of sodium–glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists), to reduce cardiovascular and kidney ...
João Sérgio Neves, Ana Rita Leite, Francisco Vasques‐Nóvoa, Bertram Pitt, Gerasimos Filippatos, Luis M. Ruilope, Peter Rossing, Stefan D. Anker, Gianluigi Savarese, Charlie A. B. Scott, Andrea Lage, Meike D. Brinker, João Pedro Ferreira   +12 more
wiley   +1 more source

Impact of Simulated Risk Factor Management on Cardiovascular Disease and Costs in Type 2 Diabetes Using the ABC Model

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims We evaluated the impact of scenario‐based multifactorial control on the 3‐year incidence of fatal/non‐fatal cardiovascular disease (CVD) and associated healthcare costs in Asian patients with type 2 diabetes (T2D). Materials and Methods We applied the validated ‘ABC’ model to simulate the 3‐year impact of attaining multiple treatment ...
Lee‐Ling Lim, Eric S. H. Lau, Juliana N. M. Lui, Linong Ji, A. G. Unnikrishnan, Sirinart Sirinvaravong, Siew‐Pheng Chan, Soo Lim, Andrea O. Y. Luk, Juliana C. N. Chan   +9 more
wiley   +1 more source

Statin use does not impair muscle health in older adults: findings from the SCOPE study. [PDF]

Aging Clin Exp Res
Fazel SD, Tap L, Fabbietti P, Corsonello A, Kob R, Sieber CC, Roller-Wirnsberger R, Wirnsberger G, Ben-Romano R, Melzer I, Kostka T, Guligowska A, Carlsson AC, Formiga F, Moreno-González R, Ärnlöv J, Lattanzio F, Mattace-Raso F, other SCOPE investigators.   +18 more
europepmc   +1 more source

Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) improve glycaemic control and cardiorenal outcomes in Type 2 diabetes, particularly in patients at elevated cardiovascular and kidney risk, yet discontinuation following infections appears common.
Christine Ljungberg, Mette Nørgaard, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Reimar Wernich Thomsen   +5 more
wiley   +1 more source

Pregnancy and neonatal outcomes following statin exposure in early pregnancy: a nationwide consultation-based cohort study in Japan. [PDF]

BMC Pregnancy Childbirth
Fujioka I, Goto M, Anzai T, Takahashi K, Koinuma S, Murashima A.   +5 more
europepmc   +1 more source

Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the associations between semaglutide initiation and long‐term skeletal outcomes in people with obesity, stratified by type 2 diabetes (T2D) status, using target trial emulation. Materials and Methods This retrospective cohort study used the TriNetX federated electronic health record network.
Yu‐Nan Huang, Min‐Yu Tsou, Pin‐Hung Li, Jo‐Ching Chen, Shao‐Chia Chen, Hao‐I Hsieh, Gideon Meyerowitz‐Katz, Yen‐Liang Liu, Pen‐Hua Su   +8 more
wiley   +1 more source

Risk of new-onset diabetes across individual statins in secondary prevention: results from the Korean national health insurance service cohort. [PDF]

Front Cardiovasc Med
Park EJ, Park Y, Kang DO, Park S, Roh SY, Na JO, Kim JW, Kim EJ, Rha SW, Park CG, Choi CU.   +10 more
europepmc   +1 more source

Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The fibrosis‐4 (FIB‐4) score is used to identify risk of advanced liver fibrosis. This post hoc analysis investigated its prognostic value for cardiovascular (CV) outcomes and its relevance to the effects of dapagliflozin. Materials and Methods DECLARE‐TIMI 58 was a randomised, placebo‐controlled phase 3 trial investigating dapagliflozin ...
Jan Oscarsson, Monika Huhn, Yunyun Jiang, Ingrid Gause‐Nilsson, Stephen D. Wiviott, Filipe A. Moura, John P. H. Wilding, Simona Cernea, Luc Van Gaal, Avivit Cahn, Deepak L. Bhatt, Peter A. Johansson, C. David Sjöström   +12 more
wiley   +1 more source